Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Alongside brand refresh, the leading clinical trial technology company announces eConsent and eCOA offerings to better support the patient clinical trial journey
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Ind-Ra expects revenue growth of over 12% in 2022.
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
The drug is also intended for the treatment of glioblastoma multiforme
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
